How Has the Monoclonal Antibodies In Veterinary Health Market Evolved Historically and What is its Current Size?
The monoclonal antibodies in veterinary health market has seen considerable growth due to a variety of factors.
• Recent years have seen a swift enlargement in the monoclonal antibodies industry for veterinary health. The market size is projected to expand from $0.8 billion in 2024 to $0.92 billion in 2025, boasting a compound annual growth rate (CAGR) of 15.2%.
The remarkable growth over this historic period can be credited to factors such as the surge in pet ownership globally, the rising incidence of chronic illnesses in animals, higher pet adoption rates, and growing health awareness among pet owners.
What is the Forecasted Market Size and CAGR for the Monoclonal Antibodies In Veterinary Health Market?
The monoclonal antibodies in veterinary health market is expected to maintain its strong growth trajectory in upcoming years.
• The veterinary health market for monoclonal antibodies is projected to exhibit swift expansion in the upcoming years, swelling to a sum of $1.61 billion by 2029 with a compound annual growth rate (CAGR) of 15.0%.
Various factors contributing towards this predicted expansion during the forecast period include a surge in the pet population, escalating expenditure on pets, the increasing instances of canine atopic dermatitis, a growing demand for high-quality veterinary healthcare, and a heightened focus on animal health. The forecast period is also expected to be marked by various trends such as progress in biotechnological research, developments in genetic engineering, out-of-the-box treatment methods, advances in antibody-based therapeutics, and technological growth in antibody engineering.
What Key Factors and Trends Are Driving The Growth Monoclonal Antibodies In Veterinary Health Market?
The growth of the monoclonal antibodies in veterinary health market is predicted to surge due to increasing incidences of animal diseases. These augmenting disease incidences are prompted by intensified farming methods that raise the possibility of infectious disease transmission, and climate change that broadens the extent of disease carriers such as ticks and mosquitoes. Monoclonal antibodies are very effective in addressing animal diseases as they specifically aim at pathogens or proteins implicated in disease development, providing exact and efficient treatments. For example, a report from the GOV.UK in June 2024 revealed that between April 2023 and March 2024, the quantity of animals slaughtered in England due to TB incidents escalated by 5% to 21,298, and rose by 17% in Wales to 11,197. These increasing incidences of animal disease are fueling the growth of the monoclonal antibodies in veterinary health market.
What Are The Market Segments In The Monoclonal Antibodies In Veterinary Health Market?
The monoclonal antibodies in veterinary health market covered in this report is segmented –
1) By Animal Type: Dogs, Other Animal Types
2) By Application: Dermatology, Pain, Other Applications
3) By End-User: Veterinary Hospitals, Other End-Users
Subsegments:
1) By Dogs: Canine Infectious Diseases, Canine Cancer Treatment, Canine Autoimmune Disorders, Canine Allergies
2) By Other Animal Types: Cats, Horses, Cattle, Swine, Poultry, Aquatic Animals, Small Mammals
Pre-Book The Monoclonal Antibodies In Veterinary Health Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Market Trends Are Altering The Monoclonal Antibodies In Veterinary Health Industry?
Leading firms in the monoclonal antibodies in veterinary health market are concentrating their efforts on creating innovative veterinary treatment options, like anti-NGF monoclonal antibody therapy, to effectively combat ongoing pain and inflammation in animals. Anti-NGF monoclonal antibody therapy is a method that aims to curb the nerve growth factor (NGF) to alleviate pain and inflammation in animals who are experiencing chronic discomfort. An example of this occurred in May 2023 when Zoetis, a U.S. animal health firm, obtained FDA authorization for Librela (bedinvetmab injection), which is the inaugural monoclonal antibody therapy designed to manage pain related to osteoarthritis (OA) in dogs. This is given as a monthly injection. Additionally, they also received approval for Apoquel Chewable, the first-ever chewable drug specifically devised to manage allergic itching and inflammation in dogs aged over one year. Librela is a monoclonal antibody that targets and restrains nerve growth factor (NGF). Blocking NGF with Librela stops these pain signals from reaching the brain, therefore reducing the perception of pain in dogs suffering from osteoarthritis. Librela is seen as a major breakthrough in veterinary pain management as it offers a new method to treat long-term pain in dogs.
Who Are the Key Players In The Monoclonal Antibodies In Veterinary Health Market?
Major companies operating in the monoclonal antibodies in veterinary health market are:
• Sanofi S.A.
• Bristol-Myers Squibb Company
• GlaxoSmithKline plc (GSK)
• Amgen Inc.
• Boehringer Ingelheim International GmbH
• Regeneron Pharmaceuticals Inc.
• Zoetis Inc.
• MSD Animal Health
• Elanco Animal Health Incorporated
• Bio-Rad Laboratories Inc.
• Eli Lilly and Company
• GenScript Biotech Corporation
• Abcam plc
• Heska Corporation
• Neogen Corporation
• iNova Pharmaceuticals
• Ceva Santé Animale S.A.
• Biogénesis Bagó S.A.
• TransGen Biotech Co. Ltd.
• AbCellera Biologics Inc.
• Areteia Therapeutics Inc.
• Esco Aster Pte Ltd
• PetMedix Ltd.
• Vaxine Pty Ltd
What Are The Regional Insights Into The Monoclonal Antibodies In Veterinary Health Market?
North America was the largest region in the monoclonal antibodies in veterinary health market in 2024. The regions covered in the monoclonal antibodies in veterinary health market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
